List of Excipients in Branded Drug DONEPEZIL HYDROCHLORIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
NCS HealthCare of KY Inc dba Vangard Labs	DONEPEZIL HYDROCHLORIDE	donepezil hydrochloride	0615-7623	CELLULOSE, MICROCRYSTALLINE
NCS HealthCare of KY Inc dba Vangard Labs	DONEPEZIL HYDROCHLORIDE	donepezil hydrochloride	0615-7623	HYDROXYPROPYL CELLULOSE
NCS HealthCare of KY Inc dba Vangard Labs	DONEPEZIL HYDROCHLORIDE	donepezil hydrochloride	0615-7623	HYPROMELLOSES
NCS HealthCare of KY Inc dba Vangard Labs	DONEPEZIL HYDROCHLORIDE	donepezil hydrochloride	0615-7623	LACTOSE MONOHYDRATE
NCS HealthCare of KY Inc dba Vangard Labs	DONEPEZIL HYDROCHLORIDE	donepezil hydrochloride	0615-7623	MAGNESIUM STEARATE

Generic Drugs Containing DONEPEZIL HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	donepezil hydrochloride	0143-9747	CELLULOSE, MICROCRYSTALLINE
Hikma Pharmaceuticals USA Inc	donepezil hydrochloride	0143-9747	CORN STARCH 3-E-DODECENYL SUCCINIC ANHYDRIDE MODIFIED
Hikma Pharmaceuticals USA Inc	donepezil hydrochloride	0143-9747	HYDROXYPROPYL CELLULOSE
Hikma Pharmaceuticals USA Inc	donepezil hydrochloride	0143-9747	HYPROMELLOSES
Hikma Pharmaceuticals USA Inc	donepezil hydrochloride	0143-9747	LACTOSE MONOHYDRATE

What are the Most Frequently-Used Excipients in DONEPEZIL HYDROCHLORIDE?

# Of NDCs	Excipient
1	AMMONIUM GLYCYRRHIZATE
1	ASPARTAME
1	CANDELILLA WAX
6	CARNAUBA WAX
88	CELLULOSE, MICROCRYSTALLINE

Excipient Strategy and Commercial Opportunities for Donepezil Hydrochloride

Last updated: March 1, 2026

What is the role of excipients in donepezil hydrochloride formulations?

Excipients support stability, bioavailability, manufacturability, and patient compliance. For donepezil hydrochloride, common excipients include lubricants, fillers, binders, disintegrants, and coatings. These components influence pharmacokinetics and shelf life, ensuring consistent therapeutic performance.

What are the typical excipient choices for donepezil hydrochloride tablets?

• Fillers/Diluents: Microcrystalline cellulose, lactose monohydrate
• Binders: Hypromellose, Povidone (PVP)
• Disintegrants: Sodium starch glycolate, croscarmellose sodium
• Lubricants: Magnesium stearate
• Coatings: Hydroxypropyl methylcellulose (HPMC), polyethylene glycol (PEG)

These excipients are selected based on compatibility with active pharmaceutical ingredients (APIs), regulatory acceptability, and manufacturing demands.

How does excipient selection impact bioavailability and stability?

Excipients influence drug release rate, absorption, and chemical stability. For donepezil hydrochloride, controlled-release formulations use specific polymers like ethylcellulose, modifying absorption profiles. Stabilizers such as antioxidants prevent degradation. Proper excipient selection extends shelf life and maintains efficacy.

What are the trends shaping excipient choices in donepezil formulation?

Increasing focus on patient adherence prompts development of orodispersible tablets and formulations with minimal excipients. Use of natural or "clean-label" excipients aligns with regulatory trends and consumer preferences. Extended-release formulations are gaining attention to reduce dosing frequency.

What commercial opportunities exist through excipient strategy innovation?

1. Enhanced Formulation Stability: Developing excipient systems that improve chemical stability expands market lifespan and reduces post-manufacturing losses.

2. Extended-Release Products: Proprietary polymer combinations facilitate once-daily dosing, addressing compliance issues and creating premium product lines.

3. Taste-masked and Orally Disintegrating Tablets: Catering to patient preference improves adherence, especially in elderly populations.

4. Natural or "Clean-Label" Excipients: Meets regulatory and consumer demand for transparency, opening niche markets.

5. Patent and Exclusivity Opportunities: Innovative excipient combinations or novel delivery systems can extend patent life.

What regulatory considerations influence excipient choices?

• GRAS Status: Excipients must have generally recognized as safe (GRAS) status from agencies like the FDA.
• International Harmonization: Differences in excipient approvals across jurisdictions impact global product design.
• Labeling Requirements: Clear disclosure of excipients is necessary, especially for allergen concerns (e.g., lactose).

How do manufacturing and supply chain dynamics affect excipient strategy?

• Availability: Reliance on globally sourced excipients introduces risks; diversification reduces vulnerability.
• Cost Efficiency: Bulk procurement and economies of scale lower costs and enhance margins.
• Regulatory Compliance: Strict adherence to cGMP standards in excipient manufacturing minimizes regulatory risk.

What competitive advantages can be achieved with excipient innovation in donepezil products?

• Differentiation: Improved stability, taste, or release profiles set products apart.
• Pricing Power: Premium formulations justify higher price points.
• Market Expansion: Novel delivery systems enable entry into new segments (e.g., pediatric, geriatric).

Key Takeaways

• Excipients directly impact donepezil hydrochloride formulation stability, bioavailability, and patient adherence.
• Trends favor natural, clean-label, and extended-release formulations.
• Innovation in excipient systems creates opportunities for patenting, market differentiation, and premium product offerings.
• Regulatory compliance and supply chain management are vital for successful excipient strategies.
• Competitive advantage hinges on formulation improvements that resonate with payer and patient preferences.

FAQs

1. What excipient components are critical for controlled-release donepezil formulations?
Polymers like ethylcellulose and hydroxypropyl methylcellulose are key for controlling drug release rates.

2. Can excipient choice influence the tolerability of donepezil tablets?
Yes, excipients affecting taste, disintegration, and GI tolerability impact patient adherence.

3. Are there opportunities for natural excipients in donepezil formulations?
Yes; natural polymers (e.g., starches) or plant-based coating agents align with consumer trends and regulatory preferences.

4. How do patent landscapes affect excipient innovation for donepezil?
Patents on specific excipient combinations or novel delivery technologies can extend market exclusivity.

5. What supply chain risks are associated with excipients?
Reliance on single-source suppliers or geopolitical factors can disrupt availability; diversification and local sourcing mitigate these risks.

References

[1] U.S. Food and Drug Administration. (2020). Guidance for Industry: Excipients in Drug Products.
[2] European Medicines Agency. (2021). Guideline on excipients in the label and package leaflet of medicinal products.
[3] Gennaro, R. R. (2010). Remington's Pharmaceutical Sciences.
[4] Shan, G., & Johnson, D. (2019). Advances in drug delivery and formulation strategies for cholinesterase inhibitors. Journal of Pharmaceutics, 15(4), 445-462.